Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

Farhad Ravandi; Stefan Faderl

doi:10.1016/j.leukres.2005.05.008

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

Farhad Ravandi, Stefan Faderl

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

30 Scopus citations

Abstract

Treatment of adult T-cell leukemia (ATL) remains difficult. Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role in this setting. However, the associated immunosuppression is a concern in patients with viral-mediated disease.

Original language	English (US)
Pages (from-to)	103-105
Number of pages	3
Journal	Leukemia Research
Volume	30
Issue number	1
DOIs	https://doi.org/10.1016/j.leukres.2005.05.008
State	Published - Jan 2006

Keywords

ATL
Alemtuzumab
HTLV-I
Pentostatin

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2005.05.008

Cite this

@article{c363a8f0f14d4a8a8339541cf6455524,

title = "Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin",

abstract = "Treatment of adult T-cell leukemia (ATL) remains difficult. Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role in this setting. However, the associated immunosuppression is a concern in patients with viral-mediated disease.",

keywords = "ATL, Alemtuzumab, HTLV-I, Pentostatin",

author = "Farhad Ravandi and Stefan Faderl",

year = "2006",

month = jan,

doi = "10.1016/j.leukres.2005.05.008",

language = "English (US)",

volume = "30",

pages = "103--105",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

AU - Ravandi, Farhad

AU - Faderl, Stefan

PY - 2006/1

Y1 - 2006/1

N2 - Treatment of adult T-cell leukemia (ATL) remains difficult. Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role in this setting. However, the associated immunosuppression is a concern in patients with viral-mediated disease.

AB - Treatment of adult T-cell leukemia (ATL) remains difficult. Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role in this setting. However, the associated immunosuppression is a concern in patients with viral-mediated disease.

KW - ATL

KW - Alemtuzumab

KW - HTLV-I

KW - Pentostatin

UR - http://www.scopus.com/inward/record.url?scp=27844536515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844536515&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.05.008

DO - 10.1016/j.leukres.2005.05.008

M3 - Comment/debate

C2 - 15979704

AN - SCOPUS:27844536515

SN - 0145-2126

VL - 30

SP - 103

EP - 105

JO - Leukemia Research

JF - Leukemia Research

IS - 1

ER -

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this